Uptake of two emerging agents from Forest/AstraZeneca/Takeda and Trius will drive MRSA drug market to $752 million in 2019
The uptake of two emerging agents from Forest/AstraZeneca/Takeda and Trius will drive the sales of methicillin-resistant Staphylococcus aureus (MRSA) drugs to increase from $631 million in 2009 to $752 million in 2019 in the major markets of the USA, France, Germany, Italy, Spain, the UK and Japan, according to the findings of advisory firm Decision Resources.
The Pharmacor 2010 findings from the topic entitled Methicillin-Resistant Staphylococcus Aureus find that Forest/AstraZeneca/Takeda's ceftaroline and Trius' torezolid will capture more than one-third of the MRSA drug market in 2019. A new drug application for ceftaroline for complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia was filed in the fourth quarter of 2009, and torezolid - a second generation oxazolidinone - is expected to begin Phase III clinical trials for cSSSI by end of 2010.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze